Pazopanib Hydrochloride
|
|
Pazopanib Hydrochloride 속성
- 녹는점
- >290°C (dec.)
- 저장 조건
- Hygroscopic, Refrigerator, under inert atmosphere
- 용해도
- 아세토니트릴(약간), DMSO(약간)에 용해됨
- 물리적 상태
- 노란색 가루.
- 색상
- 흰색에서 황백색까지
- 안정성
- 흡습성
- InChIKey
- MQHIQUBXFFAOMK-UHFFFAOYSA-N
- SMILES
- CC1N(N=C2C=C(N(C3C=CN=C(NC4C=CC(C)=C(S(=O)(=O)N)C=4)N=3)C)C=CC=12)C.Cl
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
그림문자(GHS): |
![]() |
||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
신호 어: | Warning | ||||||||||||||||||||||||||||||||||||||||||
유해·위험 문구: |
|
||||||||||||||||||||||||||||||||||||||||||
예방조치문구: |
|
Pazopanib Hydrochloride C화학적 특성, 용도, 생산
개요
Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is an oral second-generation multitarget TKI developed by GSK and approved for marketing by the FDA in 2009 and the EMA in 2010. It targets the VEGFR, platelet-derived growth factor receptor, and c-kit, key proteins responsible for tumor growth and survival. It is used to treat patients with advanced RCC and advanced soft tissue sarcoma who have experienced chemotherapy. Pazopanib Hydrochloride has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist, a tyrosine kinase inhibitor, and an angiogenesis-modulating agent.용도
Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.정의
ChEBI: A hydrochloride salt prepared from equimolar amounts of pazopanib and hydrochloric acid. Used for treatment of kidney cancer.Clinical Use
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/b, and c-kit that blocks tumor growth and inhibits angiogenesis. It was approved for renal cell carcinoma by the U.S. Food and Drug Administration in 2009 and is marketed under the trade name Votrient by the drug’s manufacturer, GlaxoSmithKline.부작용
Pazopanib is synthesized in five chemical steps starting from 3-methyl-6-nitroindazole, which is converted to the corresponding 2,3-dimethylindazole analog via N-methylation with trimethyloxonium tetrafluoroborate. Subsequent reduction of the nitro group to the amino group using tin chloride followed by condensation with 2,4dichloropyrimidine yields a chloropyrimidinylaminoindazole intermediate. The final two steps leading up to pazopanib consist of an N-methylation reaction using iodomethane and cesium carbonate followed by condensation with 5-amino-2-methylbenzenesulfonamide.참고 문헌
[1] Sodeifian, G. et al. “Solubility of pazopanib hydrochloride (PZH, anticancer drug) in supercritical CO2: Experimental and thermodynamic modeling.” The Journal of Supercritical Fluids 55 1 (2022): 0.[2] “Stability Indicating HPTLC Method Development and Validation for the Estimation of Pazopanib Hydrochloride in Bulk and its Dosage Form.” International Journal of Pharmaceutical Research 18 1 (2020).
[3] K. Kawasaki . “Retrospective Safety Analysis in Advanced Soft Tissue Sarcoma Patients of Pazopanib Hydrochloride.” Annals of Oncology 24 (2013): Page ix38.
[4] Gupta, Amit and Rashmi Dahima. “Application of Simplex Lattice Mixture design and desirability function in the development and Optimization of SEDDS for protein kinase inhibitor-Pazopanib Hydrochloride.” Research Journal of Pharmacy and Technology 83 1 (2023): 0.
Pazopanib Hydrochloride 준비 용품 및 원자재
원자재
준비 용품
Pazopanib Hydrochloride 공급 업체
글로벌( 307)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
AFINE CHEMICALS LIMITED | +86-0571-85134551 |
info@afinechem.com | China | 15395 | 58 |
BIONNA MEDICINE CO.,LTD | 01056380788-8515; +8618518759099 |
790226113@qq.com | China | 52 | 58 |
Yangzhou Qinyuan Pharmatech Co.,ltd | +86-18752526868 |
jennysun@yzqyyykj.com | China | 71 | 58 |
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 |
sales@sjar-tech.com | China | 123 | 58 |
Beijing Cooperate Pharmaceutical Co.,Ltd | 010-60279497 |
sales01@cooperate-pharm.com | CHINA | 1811 | 55 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21668 | 55 |
Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9332 | 55 |
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32760 | 60 |
Anqing Chico Pharmaceutical Co., Ltd. | 15380796838 |
chloewu@chicopharm.cn | CHINA | 341 | 58 |
Lianyungang happen teng technology co., LTD | 15950718863 |
wang666xt@163.com | CHINA | 295 | 58 |
Pazopanib Hydrochloride 관련 검색:
Palonosetron Hydrochloride
Afatinib
4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide hydrate
Cabazitaxel
Lapatinib ditosylate
Afatinib dimaleate
AZD-9291
Nintedanib Ethanesulfonate Salt
Pazopanib
2,3-DIMETHYL-6-NITRO-2H-INDAZOLE
2,3-dimethyl-2H-indazol-6-amine hydrochloride
2-Ethyl-5-nitrobenzenamine ,98%
3-Methyl-6-nitroindazole
Sorafenib tosylate
Gefitinib
Axitinib
Dasatinib
Regorafenib